Skip to main content

Search

In the News

In the News

Janssen and Johnson & Johnson spokespeople are providing regular updates to UK media on our response to the COVID-19 pandemic

August 14 - Dr Paul Stoffels speaks to Sky News

Oncology

 

Today, our Chief Scientific Officer Dr Paul Stoffels spoke to Sky News following the announcement of an agreement in principle between Johnson & Johnson and UK Government..

June 12 - Professor Hanneke Schuitemaker speaks to Sky News

Oncology

 

Professor Hanneke Schuitemaker, our Global Head of Viral Vaccine Discovery and Translational Medicine, spoke on Ian King Live about our accelerated initiation of the Phase 1/2a first-in-human clinical trials of our investigational SARS-CoV-2 vaccine.

Hanneke also touched on how Johnson & Johnson’s efforts to ramp up the development and production of a SARS-CoV-2 vaccine are enhanced by a collaboration between Janssen and the Biomedical Advanced Research and Development Authority (BARDA).

------------------------------------------------------------------------------------------------------------------------------------------------------------------------

March 31 - Dr Paul Stoffels speaks to Sky News

Oncology

 

 

 

 

 

 

 

 

 

 

 

 

 

We remain committed to addressing the global COVID19 crisis.

Today, our Chief Scientific Officer Dr Paul Stoffels spoke to Sky News about our announcement of a lead vaccine candidate and plans to initiate human clinical studies.

------------------------------------------------------------------------------------------------------------------------------------------------------------------------

March 13 - Professor Hanneke Schuitemaker on The Science Media Centre Panel

Taking a united approach to combat coronavirus

On March 13, Janssen was invited to take part in a Science Media Centre media briefing on the development of potential treatments for coronavirus (COVID-19), held in London.

Here, Professor Hanneke Schuitemaker, our Global Head of Viral Vaccine Discovery and Translational Medicine, and Disease Area Stronghold Leader for Viral Vaccines, spoke about our multi-pronged approach to combat COVID-19.

 

---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

March 6 - Johan Van Hoof live on BBC News

 

Oncology

 

As a leader in global health, Johnson & Johnson is on the front line of the coronavirus (COVID-19) health crisis, bringing our full resources and minds to combat it.

Today our Global Head of Vaccines, Johan Van Hoof spoke to BBC News about our efforts to accelerate the development of a vaccine.

---------------------------------------------------------------------------------------------------------------------------------------------------------------------------